Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 1

Status

Recruiting 4Available 1Active not recruiting 1

Sponsor Class

OTHER 5NETWORK 1

Study Type

Interventional 5Expanded_access 1

Sponsor

Cancer Type

CNS 6Sarcoma 1

Conditions

Neuroblastoma 6Sarcoma, Ewing 2Osteosarcoma 2Neuroectodermal Tumors, Primitive 2Medulloblastoma 2Glioma 2Glioblastoma 2Astrocytoma 2Typical Teratoid Rhabdoid Tumor 1Rhabdoid Tumor 1Prostatic Neoplasms 1Osteosarcoma Recurrent 1Oligodendroglioma 1Non-melanoma Skin Cancer 1Melanoma 1Lymphoma, Follicular 1Lung Neoplasms 1Diffuse Intrinsic Pontine Glioma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Cyclophosphamide 28Temozolomide 25Irinotecan 21dinutuximab 20Topotecan 15Magnetic Resonance Spectroscopy 13Specimen Handling 12Biopsy 12naxitamab 11Granulocyte-Macrophage Colony-Stimulating Factor 113-Iodobenzylguanidine 11Vincristine 10Etoposide 10sargramostim 9Melphalan 9Isotretinoin 9fludarabine 8X-Rays 8Colony-Stimulating Factors 8Carboplatin 8etoposide phosphate 7Phantoms, Imaging 7Doxorubicin 7fludarabine phosphate 6Stem Cell Transplantation 6Nuclear Medicine Department, Hospital 6Eflornithine 6Thiotepa 5Granulocyte Colony-Stimulating Factor 5Filgrastim 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Neuroblastoma × Eflornithine × 1 year × Clear all
NCT06465199 2026-06-03

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

Milton S. Hershey Medical Center

Phase 1/2 Recruiting
289 enrolled
CNSSarcoma

Diffuse Intrinsic Pontine Glioma, Neuroblastoma, Sarcoma, Ewing, Osteosarcoma, Neuroectodermal Tumors, Primitive, Rhabdoid Tumor

NCT02559778 2026-04-28

PEDS-PLAN

Milton S. Hershey Medical Center

Phase 2 Recruiting
500 enrolled
CNS

Neuroblastoma

NCT03581240 2026-02-20

An Intermediate Expanded Use Trial of DFMO

Milton S. Hershey Medical Center

Available
CNS

Typical Teratoid Rhabdoid Tumor, Medulloblastoma, Neuroblastoma, Neuroectodermal Tumors, Primitive

NCT03794349 2026-02-18

Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma

Children's Oncology Group

Phase 2 Active not recruiting
94 enrolled 14 charts
CNS

Neuroblastoma

NCT04301843 2026-02-03

Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma

Milton S. Hershey Medical Center

Phase 2 Recruiting
131 enrolled
CNS

Neuroblastoma

NCT02679144 2026-01-21

NMTT

Milton S. Hershey Medical Center

Phase 2 Recruiting
441 enrolled
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡